Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
18. März 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.Amyloid Light...
TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals
16. November 2020 11:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication...
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
08. Oktober 2020 06:00 ET
|
Cytovia Therapeutics
NEW YORK and PARIS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement...
Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) Platform
14. September 2020 06:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has entered into an exclusive license agreement with Mayo Clinic for a...
Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
26. Mai 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its...
Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
06. November 2019 19:37 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy
19. Juni 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
“CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic considerations○ Clinical...
Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
11. April 2018 07:30 ET
|
Actinium Pharmaceuticals
- In vivo data to be presented via poster highlighting the ability of Actinium’s AWE Technology to yield increased cell killing power, survival benefit and a potential biobetter of daratumumab, a...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
08. Februar 2018 08:00 ET
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
05. Februar 2018 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...